Considering the evidence that ERCC1 could be a potential therapeutic target for enhancing responses to platinum-based chemotherapy in lung cancer, the development of small molecule inhibitors of XPF nuclease activity has been the focus of several studies from multiple research groups [17,18,19,20,21,22]. This evidence concerns the gene ERCC4 and lung cancer.